Breadcrumb
Dokumente & Medien
Bayesian models for aggregate and individual patient data component network meta-analysis
Bayesian models for aggregate and individual patient data component network meta-analysis
Version 1.0 Genehmigt- Dokumententyp
- EXTERNAL_DOCUMENT
- Erweiterung
- png
- Größe
- 170 KB
- Geändert
- 21.10.22 13:16 von mir mir
- Erstellt
- 21.10.22 13:16 von mir mir
- Ort
- PUBLIC
- Bewertungen
-
-
Version 1.0Von mir mir, am 21.10.22 13:16Kein Änderungsprotokoll
Kurzfassung
Abstract
Network meta-analysis can synthesize evidence from studies comparing multiple treatments for the same disease. Sometimes the treatments of a network are complex interventions, comprising several independent components in different combinations. A component network meta-analysis (CNMA) can be used to analyze such data and can in principle disentangle the individual effect of each component. However, components may interact with each other, either synergistically or antagonistically. Deciding which interactions, if any, to include in a CNMA model may be difficult, especially for large networks with many components. In this article, we present two Bayesian CNMA models that can be used to identify prominent interactions between components. Our models utilize Bayesian variable selection methods, namely the stochastic search variable selection and the Bayesian LASSO, and can benefit from the inclusion of prior information about important interactions. Moreover, we extend these models to combine data from studies providing aggregate information and studies providing individual patient data (IPD). We illustrate our models in practice using three real datasets, from studies in panic disorder, depression, and multiple myeloma. Finally, we describe methods for developing web-applications that can utilize results from an IPD-CNMA, to allow for personalized estimates of relative treatment effects given a patient's characteristics.
Das COMPAR-EU-Projekt wurde durch das Forschungs- und Innovationsprogramm Horizont 2020 der Europäischen Union unter der Fördervereinbarung Nr. 754936 gefördert.
Sie enthält jetzt die vollständigen Ergebnisse für Diabetes, und im Laufe des Sommers 2022 werden die Ergebnisse für Adipositas, COPD und Herzinsuffizienz vervollständigt. Die Plattform wird auch in den nächsten Monaten erweitert und verbessert.